ArticleAnnals of the rheumatic diseases2019

Response to: 'Comment on: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg.

Eric F Morand et al.PubMed ↗Publisher ↗

No numbers read from the abstract.